Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
GALATIR is a double blind randomized clinical trial comparing efficacy and safety of BCD-021 (bevacizumab) and Lucentis® (ranibizumab) in patients with neovascular wet age-related macular degeneration. The purpose of the study is to demonstrate the non-inferiority of efficacy and safety of BCD-021 compared to Lucentis®.
Epistemonikos ID: 77fc30272b868b60e404a52f10f28e5234cc9ffe
First added on: May 11, 2024